Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is a rapid cardiac arrhythmia originating above the ventricles, specifically within the sinus node, atrial myocardium, atrioventricular (AV) node, or accessory pathways. It is characterized by a heart rate exceeding the normal physiological range for the species and age, with a narrow QRS complex (unless aberrant conduction or bundle branch block coexists). SVT encompasses several distinct electrophysiological mechanisms, including enhanced automaticity, triggered activity (early or delayed afterdepolarizations), and reentry. In veterinary medicine, SVT is a common clinical entity in dogs and less frequently in cats, often associated with structural heart disease, systemic disorders, or as a primary electrical disease. The clinical significance ranges from an incidental finding to a life-threatening hemodynamic compromise, potentially leading to syncope, congestive heart failure, or sudden cardiac death. Accurate diagnosis and differentiation from ventricular tachycardia are crucial for appropriate management and prognosis.

The etiology of SVT is diverse and can be classified into primary (idiopathic) and secondary causes. Primary SVT arises from intrinsic electrophysiological abnormalities, such as accessory pathways (e.g., Wolff-Parkinson-White syndrome in dogs), AV nodal reentry, or enhanced automaticity in atrial foci. Secondary causes include structural heart diseases like mitral valve disease, dilated cardiomyopathy, hypertrophic cardiomyopathy (in cats), congenital heart defects (e.g., atrial septal defect), and myocarditis (infectious, immune-mediated, or toxic). Systemic conditions such as hyperthyroidism (feline), pheochromocytoma, sepsis, hypoxia, electrolyte imbalances (hypokalemia, hypomagnesemia, hypercalcemia), and acid-base disturbances can precipitate SVT. Drug-induced SVT may occur with sympathomimetics, theophylline, or digitalis toxicity. In some cases, SVT is associated with exercise, stress, or pain. Genetic predispositions have been identified in certain breeds, such as the Boxer with arrhythmogenic right ventricular cardiomyopathy, which can also manifest atrial arrhythmias.

SVT is more commonly diagnosed in dogs than in cats. In dogs, it accounts for approximately 10-15% of all arrhythmias. Certain breeds are overrepresented: Labrador Retrievers, Golden Retrievers, German Shepherds, and Boxers. Age of onset varies; congenital SVT (e.g., accessory pathways) may present in young animals, while acquired SVT is more common in middle-aged to older animals with underlying cardiac disease. No significant sex predilection is consistently reported. In cats, SVT is less frequent but may be seen in hypertrophic cardiomyopathy or hyperthyroidism. The exact incidence is unknown due to the intermittent nature of the arrhythmia and the need for electrocardiographic monitoring for detection. In a referral population, SVT was identified in 2-5% of dogs undergoing ambulatory ECG monitoring.

The pathophysiology of SVT depends on the underlying mechanism. Reentrant tachycardias require a substrate with two distinct conduction pathways (e.g., AV nodal reentry) or an accessory pathway (e.g., orthodromic AV reentrant tachycardia). A premature beat initiates reentry if one pathway exhibits unidirectional block and the other has slow conduction, allowing the impulse to circulate and sustain tachycardia. Enhanced automaticity results from abnormal spontaneous depolarization in atrial or AV nodal cells, often due to increased sympathetic tone, hypokalemia, or ischemia. Triggered activity arises from afterdepolarizations, which are oscillations in membrane potential following an action potential; early afterdepolarizations occur during phase 2 or 3, while delayed afterdepolarizations occur after repolarization, often due to intracellular calcium overload. The rapid ventricular rate reduces diastolic filling time, decreases stroke volume, and increases myocardial oxygen demand, leading to hypotension, reduced coronary perfusion, and potential myocardial ischemia. Chronic or sustained SVT can cause tachycardia-induced cardiomyopathy, characterized by ventricular dilation and systolic dysfunction, which is reversible with rate control or rhythm conversion.

Predisposing factors for SVT include underlying structural heart disease (e.g., myxomatous mitral valve degeneration, dilated cardiomyopathy, hypertrophic cardiomyopathy), congenital abnormalities (e.g., Ebstein's anomaly, accessory pathways), and systemic diseases such as hyperthyroidism, pheochromocytoma, and sepsis. Electrolyte imbalances, particularly hypokalemia and hypomagnesemia, increase the risk of arrhythmias. Hypoxia and acid-base disturbances can also predispose. Certain drugs, including digoxin, sympathomimetics, and methylxanthines, may trigger SVT. Stress, anxiety, and pain increase sympathetic tone, facilitating the initiation of SVT. In some breeds, genetic mutations affecting ion channels (e.g., sodium or potassium channels) have been implicated in familial atrial fibrillation and other SVTs.

Clinical signs of SVT vary from asymptomatic to severe. In asymptomatic animals, SVT may be an incidental finding during routine examination. When symptomatic, common signs include weakness, lethargy, exercise intolerance, and syncope. Owners may report episodes of collapse or 'fainting' that resolve spontaneously. In severe cases, signs of congestive heart failure may develop, such as dyspnea, cough, and ascites. Physical examination findings include tachycardia (heart rate >180 bpm in dogs, >240 bpm in cats), weak or variable pulse quality, and possibly signs of underlying heart disease (e.g., heart murmur, gallop rhythm). In cats, SVT may be associated with hypertrophic cardiomyopathy, and clinical signs may include respiratory distress due to pulmonary edema. In some cases, SVT is paroxysmal, and the animal appears normal between episodes.

Differential diagnoses for SVT include other tachyarrhythmias and conditions that cause similar clinical signs. Key differentials are: 1) Ventricular tachycardia (VT) – distinguished by wide QRS complexes (>0.06 s in dogs, >0.04 s in cats) and AV dissociation; 2) Sinus tachycardia – gradual onset/offset, rate usually <180 bpm in dogs, and associated with physiological stimuli (fever, pain, excitement); 3) Atrial fibrillation – irregularly irregular rhythm with no P waves, often with underlying atrial enlargement; 4) Atrial flutter – sawtooth flutter waves, regular ventricular response; 5) Accelerated idioventricular rhythm – wide QRS, rate 60-100 bpm, often benign; 6) Hyperthyroidism – causes sinus tachycardia or atrial fibrillation, diagnosed by thyroid hormone levels; 7) Sepsis or systemic inflammatory response syndrome – may cause sinus tachycardia; 8) Pheochromocytoma – episodic hypertension and tachycardia; 9) Anxiety or pain – causes sinus tachycardia; 10) Drug toxicity (e.g., digoxin) – can cause various arrhythmias. Definitive differentiation requires electrocardiography (ECG) and possibly electrophysiological studies.

The diagnostic approach to SVT begins with a thorough history and physical examination. If SVT is suspected, a baseline ECG should be obtained. If the arrhythmia is not captured on a standard ECG, ambulatory monitoring (Holter monitor or event recorder) is indicated to document the arrhythmia and correlate with clinical signs. A minimum database includes complete blood count, serum biochemistry, and urinalysis to identify underlying systemic diseases. Serum thyroid hormone levels (total T4, free T4) are recommended in cats to rule out hyperthyroidism. Thoracic radiographs are essential to evaluate heart size, pulmonary vasculature, and signs of congestive heart failure. Echocardiography is crucial to assess cardiac structure and function, identify underlying heart disease, and evaluate for tachycardia-induced cardiomyopathy. In cases where the mechanism of SVT is unclear or for therapeutic planning, an electrophysiological study may be performed, but this is rarely available in veterinary practice. Advanced imaging such as cardiac MRI may be indicated in specific cases. The diagnostic algorithm should be stepwise: 1) Confirm arrhythmia with ECG; 2) Classify as SVT vs. VT; 3) Identify underlying causes; 4) Assess hemodynamic stability; 5) Determine need for acute vs. chronic therapy.

Laboratory findings in SVT are often nonspecific but may reflect underlying etiologies. Complete blood count may show leukocytosis if infection or inflammation is present. Serum biochemistry may reveal electrolyte abnormalities (hypokalemia, hypomagnesemia, hypercalcemia), elevated liver enzymes due to passive congestion, or elevated renal parameters if hypoperfusion occurs. In cats, total T4 is elevated in hyperthyroidism. Cardiac biomarkers such as NT-proBNP may be elevated in animals with heart disease, but are not specific for SVT. Troponin I may be elevated if myocardial ischemia or injury is present. Blood gas analysis may show metabolic acidosis or hypoxia in severe cases. Urinalysis is generally unremarkable unless concurrent disease exists. In cases of suspected pheochromocytoma, plasma or urine metanephrines may be measured. Genetic testing for breed-specific mutations (e.g., Boxer arrhythmogenic cardiomyopathy) may be considered.

Imaging plays a vital role in the evaluation of SVT. Thoracic radiographs may reveal cardiomegaly, pulmonary edema, or pleural effusion in cases of congestive heart failure. In dogs with myxomatous mitral valve disease, left atrial enlargement and pulmonary venous congestion may be seen. Echocardiography is the primary imaging modality: it assesses chamber dimensions, wall thickness, systolic function (ejection fraction, fractional shortening), and diastolic function. In tachycardia-induced cardiomyopathy, left ventricular dilation and reduced systolic function are observed, which may normalize after rate control. In cats with hypertrophic cardiomyopathy, concentric left ventricular hypertrophy and left atrial enlargement are typical. Doppler echocardiography can evaluate valvular regurgitation and estimate pulmonary artery pressure. Advanced imaging such as cardiac MRI may be used to detect myocardial fibrosis or inflammation, but is rarely indicated. In cases of suspected congenital heart disease, echocardiography is diagnostic.

Cytology and histopathology are not typically performed for the diagnosis of SVT itself, but may be indicated to evaluate underlying myocardial disease. Endomyocardial biopsy, though rarely performed in veterinary patients, can reveal myocarditis, fibrosis, or infiltration. Histopathological findings in tachycardia-induced cardiomyopathy include myocyte hypertrophy, interstitial fibrosis, and vacuolization. In arrhythmogenic right ventricular cardiomyopathy, fibrofatty replacement of the myocardium is characteristic. In cases of myocarditis, inflammatory infiltrates (lymphocytic, neutrophilic) and myocyte necrosis may be seen. These findings are not specific to SVT but help identify the underlying etiology.

Treatment of SVT depends on the hemodynamic stability of the patient and the underlying cause. In unstable animals with severe hypotension, syncope, or congestive heart failure, immediate electrical cardioversion (synchronized) is indicated. If electrical cardioversion is unavailable, acute medical therapy may be attempted with intravenous antiarrhythmic drugs. For stable animals, the goal is to control the ventricular rate or convert to sinus rhythm. First-line therapy for acute management includes intravenous diltiazem (0.25 mg/kg over 2-3 minutes, then CRI at 2-6 mcg/kg/min) or esmolol (0.5 mg/kg IV bolus, then CRI at 50-200 mcg/kg/min). For chronic management, oral diltiazem (0.5-1.5 mg/kg PO q8h) or beta-blockers such as atenolol (0.25-1 mg/kg PO q12h) are commonly used. Digoxin may be used in cases of atrial fibrillation with concurrent heart failure, but is less effective for SVT. In refractory cases, amiodarone (10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg q24h) or sotalol (1-2 mg/kg PO q12h) may be considered. Underlying conditions (e.g., hyperthyroidism, electrolyte imbalances) must be addressed. In cases of tachycardia-induced cardiomyopathy, aggressive rate control often leads to resolution of systolic dysfunction. Surgical or catheter-based ablation of accessory pathways is rarely performed in veterinary medicine but may be considered in specialized centers.

The prognosis for SVT varies widely depending on the underlying cause, duration, and response to therapy. In animals with paroxysmal SVT and no structural heart disease, the prognosis is generally good with appropriate medical management. However, if SVT is sustained and untreated, it can lead to tachycardia-induced cardiomyopathy, which is reversible with rate control. The prognosis is guarded in animals with severe underlying heart disease (e.g., dilated cardiomyopathy, severe mitral regurgitation) or those that develop congestive heart failure. In cats with hypertrophic cardiomyopathy and SVT, the prognosis is more guarded due to the risk of thromboembolism and progressive heart failure. Negative prognostic indicators include the presence of syncope, congestive heart failure, severe ventricular dysfunction, and failure to control the arrhythmia. With appropriate therapy, many animals can have a good quality of life for months to years.

Follow-up for animals with SVT includes regular re-evaluations to assess heart rate control, clinical signs, and progression of underlying disease. Initially, re-check should occur 1-2 weeks after initiating or adjusting therapy. A Holter monitor may be used to assess the burden of SVT and the efficacy of antiarrhythmic drugs. Serial echocardiography is recommended every 3-6 months to monitor cardiac function and chamber dimensions, especially in cases of tachycardia-induced cardiomyopathy. Blood pressure measurement and routine bloodwork (electrolytes, renal function) should be performed periodically, especially if using drugs like digoxin or amiodarone. Owners should be educated to monitor resting heart rate and report any episodes of weakness or collapse. Long-term management may require dose adjustments based on clinical response and side effects.

Pearls: 1) Always obtain a baseline ECG during tachycardia; a narrow QRS complex suggests SVT, but aberrant conduction can mimic VT. 2) Vagal maneuvers (carotid sinus massage, ocular pressure) may slow or terminate SVT, aiding in diagnosis. 3) In unstable patients, synchronized cardioversion is the treatment of choice; do not delay. 4) Tachycardia-induced cardiomyopathy is reversible; aggressive rate control can normalize systolic function. 5) In cats, always rule out hyperthyroidism before starting antiarrhythmic therapy. Pitfalls: 1) Misdiagnosing SVT as VT and treating with lidocaine, which is ineffective for SVT. 2) Using digoxin as a first-line agent for SVT; it may increase automaticity and worsen the arrhythmia. 3) Failing to address electrolyte imbalances, which can perpetuate arrhythmias. 4) Overlooking underlying structural heart disease, which may require specific therapy. 5) Inadequate dosing of diltiazem or beta-blockers, leading to suboptimal rate control.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended for SVT: 1) Diltiazem: For acute control, IV bolus of 0.25 mg/kg over 2-3 minutes, followed by CRI at 2-6 mcg/kg/min. For chronic oral therapy, 0.5-1.5 mg/kg PO q8h (dogs) or 1-2 mg/kg PO q8h (cats). 2) Esmolol: IV bolus of 0.5 mg/kg over 1 minute, then CRI at 50-200 mcg/kg/min, titrated to effect. 3) Atenolol: 0.25-1 mg/kg PO q12h (dogs) or 0.25-0.5 mg/kg PO q12h (cats). 4) Sotalol: 1-2 mg/kg PO q12h (dogs); not recommended in cats due to proarrhythmic risk. 5) Amiodarone: 10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg PO q24h (dogs); use with caution due to hepatotoxicity and thyroid effects. 6) Digoxin: 0.005-0.01 mg/kg PO q12h (dogs) or 0.007 mg/kg PO q48h (cats); monitor for toxicity. 7) For emergency cardioversion, use synchronized electrical shock at 0.5-1 J/kg. Always adjust doses in renal or hepatic impairment and monitor for drug interactions.

Evidence-based literature on SVT in veterinary medicine is limited but growing. A retrospective study by Santilli et al. (2018) evaluated the efficacy of diltiazem in dogs with atrial fibrillation and found good rate control. Another study by Côté et al. (2004) described the use of amiodarone for refractory SVT in dogs. ACVIM consensus guidelines on the diagnosis and treatment of arrhythmias (2018) provide recommendations for the management of SVT, emphasizing the importance of identifying underlying heart disease. In cats, a study by Ferasin et al. (2003) reported the use of atenolol for hypertrophic cardiomyopathy and arrhythmias. Tachycardia-induced cardiomyopathy has been well-documented in dogs, with studies showing reversibility after rate control (e.g., Wright et al., 1999). Overall, the evidence supports the use of calcium channel blockers and beta-blockers as first-line therapy, with amiodarone reserved for refractory cases. Further research is needed to establish optimal protocols and long-term outcomes.